Bemarituzumab

Tax included
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.
MedChemExpress 
HY-P99010

Data sheet

Size
Multiple sizes
Reactivity
FGFR
Application
Cancer-Kinase/protease
CAS
1952272-74-0